Aardvark Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of safe and effective small molecule therapeutics. The company's lead product, ARD 101, is an oral drug designed to have low systemic exposure while activating gut peptide hormone secretion and gut-brain signaling. This innovative approach aims to treat a variety of metabolic and inflammatory diseases. Aardvark Therapeutics operates in the biopharmaceutical market, primarily serving patients with complex medical conditions that require advanced therapeutic solutions. The company generates revenue through the development and eventual commercialization of its drug candidates, with a focus on achieving regulatory approval and market entry.

Chief Medical Officer Dr. Andreas Niethammer, who has extensive experience in translational medicine and executive roles at major pharmaceutical companies, leads the clinical development efforts.

Key aspects of Aardvark's business model include leveraging preclinical and clinical data to support the efficacy and safety of its drug candidates, and focusing on the therapeutic potential of bitter taste receptors (Tas2Rs), which are expressed on many cells throughout the body.

The company aims to address unmet medical needs by providing novel treatments that offer broad therapeutic potential.

Keywords: small molecule therapeutics, gut-brain signaling, metabolic diseases, inflammatory diseases, clinical-stage, biopharmaceutical, ARD 101, Tas2Rs, peptide hormone secretion, innovative treatments.